No Data
US Stock MarketDetailed Quotes
IMGN ImmunoGen
Watchlist
29.220
0.0000.00% Trading 12/05 11:15 ET
29.280High29.110Low4.01MVolume
29.150Open29.220Pre Close117.02MTurnover1.62%Turnover RatioLossP/E (TTM)7.78BMarket Cap29.44052wk HighLossP/E (Static)266.26MShares3.60552wk Low13.85P/B7.24BFloat Cap45.500Historical High--Dividend TTM247.79MShs Float0.719Historical Low--Div YieldTTM0.58%Amplitude29.203Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About ImmunoGen Company
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
License and milestone fees76.03M69.89%
Non-cash royalty revenue related to the sale of future royalties29.26M26.90%
Product revenue, net2.55M2.35%
Research and development support940K0.86%
News
ImmunoGen Bags Priority Review for Full Approval of Ovarian Cancer Drug
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE (Mirvetuximab Soravtansine-Gynx) in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed
Analysts Conflicted on These Healthcare Names: Natera (NTRA), ImmunoGen (IMGN) and Pfizer (PFE)
Comments
Third Bridge views AbbVie's acquisition as a 'win-win', as Immunogen may gain leverage from its early mover advantage under AbbVie's ownership, despite potential threats from Daiichi Sankyo's therapy R-DXd, as stated by Truist.
$ImmunoGen(IMGN.US$ I'm getting in
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--